Vertex has signed a reimbursement agreement GKV-Spitzenverband, the umbrella organization for all public health insurers in Germany, for the company’s CRISPR/Cas9 gene-edited therapy, Casgevy.
The agreement secures sustainable access to the one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.
With this agreement, Germany joins a growing number of countries that have reimbursed Casgevy, including Austria, Denmark, Italy, the Kingdom of Saudi Arabia, the United Arab Emirates, the UK and the U.S.
Casgevy, co-developed with CRISPR Therapeutics, was approved by the U.S. FDA in December 2023, as the first gene-edited cell therapy for patients with sickle cell disease. In early 2024, its approval was expanded to include the treatment of transfusion-dependent beta thalassemia in patients 12 years and older. In December 2025, Vertex announced the first presentation of clinical data from pivotal studies in children ages 5-11 years with SCD and TDT.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!